Potent Antitumor Activity of Interleukin-27

Cancer Research

Volumn 64, Issue 3, 2004, Pages 1152-1156

  Hisada, Masayuki ^a,b   Kamiya, Sadahiro ^a   Fujita, Koji ^b   Belladonna, Maria Laura ^c   Aoki, Tatuya ^b   Koyanagi, Yasuhisa ^b   Mizuguchi, Junichiro ^a   Yoshimoto, Takayuki ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 27; NEUTRALIZING ANTIBODY; STAT4 PROTEIN; T BET ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG TOXICITY; GENE THERAPY; GENETIC TRANSDUCTION; IMMUNITY; IN VIVO STUDY; INTERFERON PRODUCTION; MOUSE; MOUSE STRAIN; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SPLEEN CELL; STRAIN DIFFERENCE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; INTERFERON TYPE II; INTERLEUKINS; MICE; MICE, INBRED BALB C; MICE, NUDE; STAT4 TRANSCRIPTION FACTOR; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0842347431     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2084     Document Type: Article

References (29)

1. Trinchieri, G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol., 13: 251-276, 1995.
2. Gately, M. K., Renzetti, L. M., Magram, J., Stern, A. S., Adorini, L., Gubler, U., and Presky, D. H. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol., 16: 495-521, 1998.
3. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., and Gately, M. K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med., 178: 1223-1230, 1993.
4. Rakhmilevich, A. L., Janssen, K., Turner, J., Culp, J., and Yang, N. S. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum. Gene Ther., 8: 1303-1311, 1997.
5. Cavallo, F., Signorelli, P., Giovarelli, M., Musiani, P., Modesti, A., Brunda, M. J., Colombo, M. P., and Forni, G. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst. (Bethesda), 89: 1049-1058, 1997.
6. Colombo, M. P., and Trinchieri, G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev., 13: 155-168, 2002.
7. Marshall, E. Cancer trial of interleukin-12 halted. Science (Wash. DC), 268: 1555, 1995.
8. Car, B. D., Eng, V. M., Lipman, J. M., and Anderson, T. D. The toxicology of interleukin-12: a review. Toxicol. Pathol., 27: 58-63, 1999.
9. Pflanz, S., Timans, J. C., Cheung, J., Rosales, R., Kanzler, H., Gilbert, J., Hibbert, L., Churakova, T., Travis, M., Vaisberg, E., Blumenschein, W. M., Mattson, J. D., Wagner, J. L., To, W., Zurawski, S., McClanahan, T. K., Gorman, D. M., Bazan. J. F., de Waal Malefyt, R., Rennick, D., and Kastelein, R. A. IL-27, a heterodimeric cytokine composed of EB13 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity, 16: 779-790, 2002.
10. Chen, Q., Ghilardi, N., Wang, H., Baker, T., Xie, M. H., Gurney, A., Grewal, I. S., and de Sauvage, F. J. Development of Th1-type immune responses requires the type 1 cytokine receptor TCCR. Nature (Lond.), 407: 916-920, 2000.
11. Yoshida, H., Hamano, S., Senaldi, G., Covey, T., Faggioni, R., Mu, S., Xia, M., Wakeham, A. C., Nishina, H., Potter, J., Saris, C. J., and Mak, T. W. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity, 15: 569-578, 2001.
12. Takeda, A., Hamano, S., Yamanaka, A., Hanada, T., Ishibashi, T., Mak, T. W., Yoshimura, A., and Yoshida, H. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol., 170: 4886-4890, 2003.
13. Szabo, S. J., Sullivan, B. M., Stemmann, C., Satoskar, A. R., Sleckman, B. P., and Glimcher, L. H. Distinct effects of T-bet in TH1 lineage commitment and IFN-γ production in CD4 and CD8 T cells. Science (Wash. DC), 295: 338-342, 2002.
14. Kaplan, M. H., Sun, Y. L., Hoey, T., and Grusby, M. J. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature (Lond.), 382: 174-177, 1996.
15. Belladonna, M. L., Renauld, J. C., Bianchi, R., Vacca, C., Fallarino, F., Orabona, C., Fioretti, M. C., Grohmann, U., and Puccetti, P. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J. Immunol., 168: 5448-5454, 2002.
16. Yoneto, T., Waki, S., Takai, T., Tagawa, Y., Iwakura, Y., Mizuguchi, J., Nariuchi, H., and Yoshimoto, T. A critical role of Fc receptor-mediated antibody-dependent phagocytosis in the host resistance to blood-stage Plasmodium berghei XAT infection. J. Immunol., 166: 6236-6241, 2001.
17. Martinotti, A., Stoppacciaro, A., Vagliani, M., Melani, C., Spreafico, F., Wysocka, M., Parmiani, G., Trinchieri, G., and Colombo, M. P. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur. J. Immunol., 25: 137-146, 1995.
18. Rodolfo, M., Zilocchi, C., Melani, C., Cappetti, B., Arioli, I., Parmiani, G., and Colombo, M. P. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J. Immunol., 157: 5536-5542, 1996.
19. + T cells and granulocyte/macrophage colony-stimulating factor. J. Exp. Med., 188: 133-143, 1998.
20. Thierfelder, W. E., van Deursen, J. M., Yamamoto, K., Tripp, R. A., Sarawar, S. R., Carson, R. T., Sangster, M. Y., Vignali, D. A., Doherty, P. C., Grosveld, G. C., and Ihle, J. N. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature (Lond.), 382: 171-174, 1996.
21. Leroy, P., Slos, P., Homann, H., Erbs, P., Poitevin, Y., Regulier, E., Colonna, F. Q., Devauchelle, P., Roth, C., Pavirani, A., and Mehtali, M. Cancer immunotherapy by direct in vivo transfer of immunomodulatory genes. Res. Immunol., 149: 681-684, 1998.
22. Rakhmilevich, A. L., Turner, J., Ford, M. J., McCabe, D., Sun, W. H., Sondel, P. M., Grota, K., and Yang, N. S. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc. Natl. Acad. Sci. USA, 93: 6291-6296, 1996.
23. Watanabe, M., Fenton, R. G., Wigginton, J. M., McCormick, K. L., Volker, K. M., Fogler, W. E., Roessler, P. G., and Wiltrout, R. H. Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL-12 production. J. Immunol., 163: 1943-1950, 1999.
24. Tahara, H., Zitvogel, L., Storkus, W. J., Robbins, P. D., and Lotze, M. T. Murine models of cancer cytokine gene therapy using interleukin-12. Ann. N. Y. Acad. Sci., 795: 275-283, 1996.
25. Golab, J., and Zagozdzon, R. Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (review). Int. J. Mol. Med., 3: 537-544, 1999.
26. Rook, A. H., Wood, G. S., Yoo, E. K., Elenitsas, R., Kao, D. M., Sherman, M. L., Witmer, W. K., Rockwell, K. A., Shane, R. B., Lessin, S. R., and Vonderheid, E. C. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood, 94: 902-908, 1999.
27. Car, B. D., Eng, V. M., Schnyder, B., LeHir, M., Shakhov, A. N., Woerly, G., Huang, S., Aguet, M., Anderson, T. D., and Ryffel, B. Role of interferon-γ in interleukin 12-induced pathology in mice. Am. J. Pathol., 147: 1693-1707, 1995.
28. Ryffel, B. Interleukin-12: role of interferon-ã in IL-12 adverse effects. Clin. Immunol. Immunopathol., 83: 18-20, 1997.
29. Nieuwenhuis, E. E., Neurath, M. F., Corazza, N., Iijima, H., Trgovcich, J., Wirtz, S., Glickman, J., Bailey, D., Yoshida, M., Galle, P. R., Kronenberg, M., Birkenbach, M., and Blumberg, R. S. Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice. Proc. Natl. Acad. Sci. USA, 99: 16951-16956, 2002.